Compare Ingersoll Rand (IR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ingersoll Rand vs TG Therapeutics Inc — how do they compare? Ingersoll Rand trades at $78.49 (market cap $30.26B), while TG Therapeutics Inc trades at $55.15 (market cap $8.16B). The key difference: Ingersoll Rand is far larger — about 3.7× TG Therapeutics Inc's market cap, and Ingersoll Rand pays a 0.1% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ingersoll Rand for 7 Days and TG Therapeutics Inc for 15 Days on average.
| IR | TGTX | |
|---|---|---|
Market Cap | $30.26B | $8.16B |
Volume | 4,017,622 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $98.76 | $59.06 |
52-Week Low | $68.54 | $26.94 |
Typical Hold Time | 7 Days | 15 Days |
Enterprise Value | $33.92B | $8.37B |
Dividend Yield | 0.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ingersoll Rand
Ingersoll Rand develops industrial technologies for creating and managing flow, pressure, and motion. Its portfolio includes compressors, pumps, vacuum systems, and other equipment used across industrial markets.
Read more on IR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
